Medical-technology/distribution unit of the Xiamen C&D trading conglomerate; exact product scope not independently confirmed.
Medical-technology/distribution unit of the Xiamen C&D trading conglomerate; exact product scope not independently confirmed.
Moat: none
Headquarters: Xiamen, Fujian, China · Employees: 2,115
Size Shanghai C and D INNOSTIC Medical Technology (301584.SZ) is a China Health Care company (Medical Distributors) with a market value of $1.06B, the 2049th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥17.13 on 18 Nov 2026.
Performance Over six months the shares fell 33.4%, against -2.3% for the median peer and -20.0% for the China market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue grew 8.4% over the last twelve months (peer median +5.0%); the operating margin is 3.1% (peer median 2.3%).
Valuation It trades at 0.5× enterprise value to sales against a peer median of 0.8× (9th cheapest of 21).
Price implies For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is -21 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.9 points above its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥19.9B | CN¥19.4B | CN¥17.9B | CN¥15.4B | CN¥11.9B |
| Revenue growth | — | +8% | +16% | +30% | — |
| Gross profit | CN¥1.62B | CN¥1.44B | CN¥1.25B | CN¥1.14B | CN¥864M |
| EBITDA | n/a | CN¥701M | CN¥646M | CN¥511M | CN¥364M |
| Net income | CN¥293M | CN¥270M | CN¥228M | CN¥196M | CN¥174M |
| Free cash flow | CN¥909M | CN¥668M | CN¥43.4M | -CN¥457M | -CN¥661M |
| Capital expenditure | CN¥72.6M | CN¥80.7M | CN¥121M | CN¥82.4M | CN¥33.5M |
| Total debt | CN¥4.67B | CN¥4.53B | n/a | CN¥3.87B | CN¥2.65B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301584.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.7% | -0.1% | 4th lowest of 21 |
| 6-month return | -33.4% | -2.3% | lowest of 21 |
| Distance from 52-week high | -57.7% | -18.5% | lowest of 21 |
| Revenue growth (TTM) | +8.4% | +5.0% | 7th highest of 21 |
| Operating margin | 3.1% | 2.3% | 10th highest of 21 |
| EV / Sales | 0.5× | 0.8× | 9th cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | -2.7% | -0.5% | 7th least demanding of 17 |
| Growth delivered (Del g) | +17.9% | +6.1% | 2nd highest of 17 |
| Hurdle (Req g minus delivered) | -20.6 pp | -5.8 pp | 2nd least demanding of 17 |
| ROIC minus cost of capital | +3.9 pp | +0.3 pp | 3rd highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai C and D INNOSTIC Medical Technology 301584.SZ | China | $1.06B | -33% | +8% | 3% | 0.5× | -2.7% | +17.9% |
| DocMorris DOCM.SW | Switzerland | $1.08B | +169% | +11% | -8% | 1.0× | n/a | n/a |
| AS ONE 7476.T | Japan | $1.10B | +25% | +10% | 12% | 1.3× | 0.0% | +6.3% |
| Shinva Medical Instrument 600587.SS | China | $1.10B | -10% | +6% | 5% | 0.6× | -6.9% | +1.2% |
| Nanjing Pharmaceutical 600713.SS | China | $999M | -2% | +3% | 2% | 0.3× | n/a | n/a |
| Guangxi LiuYao 603368.SS | China | $975M | +1% | +2% | 5% | 0.4× | -9.7% | +6.0% |
| Arjo ARJO-B.ST | Sweden | $974M | +42% | 0% | 8% | 1.3× | -1.0% | +3.9% |
| Entero Healthcare Solutions ENTERO.NS | India | $925M | +60% | +35% | 4% | 1.2× | 24.7% | +29.9% |
| Shanghai Haohai Biological Technology 6826.HK | Hong Kong | $897M | -24% | -5% | -2% | 1.9× | 17.0% | +12.4% |
| Ship Healthcare 3360.T | Japan | $1.38B | +19% | +6% | 3% | 0.2× | -14.5% | +7.6% |
| Neuca NEU.WA | Poland | $795M | -9% | +8% | 2% | 0.3× | 5.3% | +8.1% |
| Redcare Pharmacy RDC.DE | Germany | $1.50B | +53% | +19% | 0% | 0.5× | n/a | n/a |
| Toho 8129.T | Japan | $1.64B | -5% | +4% | 1% | 0.1× | -4.6% | +5.1% |
| Arata 2733.T | Japan | $576M | -3% | +3% | 1% | 0.1× | -6.2% | +3.8% |
| Shanghai New World 600628.SS | China | $573M | -10% | -2% | 6% | 2.1× | -1.6% | +1.0% |
| GKHT Medical Technology 301370.SZ | China | $525M | -24% | -11% | 1% | 0.7× | 13.1% | +7.5% |
| Suzuken 9987.T | Japan | $2.36B | +8% | +5% | 1% | 0.1× | -10.4% | +3.2% |
| Shanghai Lily & Beauty Cosmetics 605136.SS | China | $449M | -28% | +5% | 2% | 1.1× | 21.1% | -18.1% |
| Thalys Medical Technology 603716.SS | China | $446M | -33% | -43% | -18% | 4.3× | n/a | n/a |
| Hanmi Science 008930.KS | South Korea | $2.58B | +48% | +6% | 4% | 2.5× | 26.0% | +9.6% |
| Asker Healthcare ASKER.ST | Sweden | $2.69B | -14% | +12% | 7% | 1.8× | 4.7% | +12.7% |